Mankind Pharma Reports Q4FY26 Results; PAT Jumps 32% YoY, Revenue Crosses Rs 14,000 Crore In FY26

The Indian equity markets traded lower on Wednesday, with the benchmark Nifty 50 index declining 0.15 per cent to 23,582.15 during the session. Pharmaceutical stocks remained in focus amid Q4 earnings announcements and acquisition-related developments across the healthcare sector. In this segment, Mankind Pharma gained 2.06 per cent to Rs 2,544.00 after the company announced its Q4FY26 and FY26 consolidated financial results along with updates related to Bharat Serums and Vaccines acquisition.

Mankind Pharma Q4FY26 Results

Mankind Pharma reported consolidated revenue from operations of Rs 3,442.93 crore in Q4FY26 as against Rs 3,079.37 crore reported in Q4FY25, registering a growth of around 11.8 per cent YoY. Total income stood at Rs 3,557.22 crore during Q4FY26 compared to Rs 3,330.70 crore reported in Q4FY25, reflecting a growth of around 6.8 per cent YoY.

Profit before Tax from continuing operations stood at Rs 659.17 crore in Q4FY26 compared to Rs 515.43 crore reported in Q4FY25, registering a growth of around 27.9 per cent YoY. Profit for the quarter came in at Rs 559.42 crore during Q4FY26 as against Rs 424.65 crore reported in Q4FY25, reflecting a growth of around 31.7 per cent YoY.

Total expenses during the quarter stood at Rs 2,877.88 crore compared to Rs 2,817.59 crore reported in the corresponding quarter previous year. The company reported exceptional items amounting to Rs 23.16 crore during the quarter, mainly related to gratuity and long-term compensated absences following Labour Code changes.

Mankind Pharma FY26 Annual Performance

For the financial year ended March 31, 2026, Mankind Pharma reported consolidated revenue from operations of Rs 14,277.64 crore as against Rs 12,207.44 crore reported in FY25, registering a growth of around 17 per cent YoY. Total income stood at Rs 14,636.43 crore during FY26 compared to Rs 12,744.23 crore reported in the previous financial year.

Profit before tax from continuing operations stood at Rs 2,332.68 crore during FY26 compared to Rs 2,516.33 crore reported in FY25. Profit for the period came in at Rs 1,938.10 crore during FY26 as against Rs 2,011.12 crore reported in FY25, reflecting a decline of around 3.6 per cent YoY.

Exceptional items during FY26 aggregated Rs 129.75 crore. These included gratuity-related expenses, long-term compensated absences, stamp duty related to intellectual property assignment agreement with Bharat Serums and Vaccines Limited (BSV), and impairment loss linked to suspension of a greenfield manufacturing project in Hyderabad by subsidiary BSV.

Bharat Serums Acquisition Update

During FY26, Mankind Pharma completed acquisition of 100 per cent stake in Bharat Serums and Vaccines Limited on October 23, 2024 for a cash consideration of Rs 13,768 crore. The transaction resulted in recognition of goodwill amounting to Rs 6,472.61 crore.

The Board also approved an additional investment of up to Rs 500 crore in wholly owned subsidiary Mankind Medicare Private Limited in one or more tranches.

About Mankind Pharma

Mankind Pharma Ltd develops, manufactures and markets pharmaceutical formulations across acute and chronic therapeutic segments along with consumer healthcare products. The company operates 32 manufacturing facilities and six R&D centres with strong domestic distribution and international presence.

What are your views on Mankind Pharma’s Q4FY26 performance and Bharat Serums acquisition strategy? Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.